Immunotherapy

OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...

IRVINE, Calif., July 31, 2026 enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward...

NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...

MADISON, Wis. – July 24, 2026 Elephas Biosciences Corporation has unveiled new preclinical data demonstrating that its elive™ functional...

SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...

RARITAN, N.J., July 23, 2026 Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical...

MIRAMAR, Fla., July 23, 2026 HCW Biologics Inc. announced a significant advancement in the development of its proprietary tetravalent...

COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...

CAMBRIDGE, Massachusetts, July 23, 2026 Nona Biosciences has announced a strategic research collaboration with the Medical University of Vienna...

JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...